XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB)
NASDAQ:XTLB
Holding XTLB?
Track your performance easily

XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) Stock Price & Analysis

95 Followers

XTLB Stock Chart & Stats


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

XTLB FAQ

What was XTL Biopharmaceuticals Ltd. Sponsored ADR’s price range in the past 12 months?
XTL Biopharmaceuticals Ltd. Sponsored ADR lowest stock price was $0.75 and its highest was $4.99 in the past 12 months.
    What is XTL Biopharmaceuticals Ltd. Sponsored ADR’s market cap?
    Currently, no data Available
    When is XTL Biopharmaceuticals Ltd. Sponsored ADR’s upcoming earnings report date?
    XTL Biopharmaceuticals Ltd. Sponsored ADR’s upcoming earnings report date is Dec 05, 2023 which is 344 days ago.
      How were XTL Biopharmaceuticals Ltd. Sponsored ADR’s earnings last quarter?
      XTL Biopharmaceuticals Ltd. Sponsored ADR released its earnings results on May 31, 2023. The company reported -$0.169 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.169.
        Is XTL Biopharmaceuticals Ltd. Sponsored ADR overvalued?
        According to Wall Street analysts XTL Biopharmaceuticals Ltd. Sponsored ADR’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does XTL Biopharmaceuticals Ltd. Sponsored ADR pay dividends?
          XTL Biopharmaceuticals Ltd. Sponsored ADR does not currently pay dividends.
          What is XTL Biopharmaceuticals Ltd. Sponsored ADR’s EPS estimate?
          XTL Biopharmaceuticals Ltd. Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does XTL Biopharmaceuticals Ltd. Sponsored ADR have?
          XTL Biopharmaceuticals Ltd. Sponsored ADR has 5,449,061 shares outstanding.
            What happened to XTL Biopharmaceuticals Ltd. Sponsored ADR’s price movement after its last earnings report?
            XTL Biopharmaceuticals Ltd. Sponsored ADR reported an EPS of -$0.169 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of XTL Biopharmaceuticals Ltd. Sponsored ADR?
              Currently, no hedge funds are holding shares in XTLB
              ---

              XTL Biopharmaceuticals Ltd. Sponsored ADR Stock Smart Score

              10
              Unlock Smart Score
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Positive
              20 days / 200 days
              Momentum
              155.67%
              12-Months-Change

              Fundamentals

              Return on Equity
              -13.07%
              Trailing 12-Months
              Asset Growth
              -11.86%
              Trailing 12-Months

              Company Description

              XTL Biopharmaceuticals Ltd. Sponsored ADR

              XTL Biopharmaceuticals Ltd is a biopharmaceutical company, which engages in the acquisition and development of pharmaceutical drugs. Its drug development program focuses on the treatment of systemic lupus erythematosus. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Regulus
              Kura Oncology
              Ovid Therapeutics
              Medicinova
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis